AGÕæÈ˹ٷ½

STOCK TITAN
  1. Home
  2. Sec-filings
  3. QNCX
  4. [8-K] Quince Therapeutics, Inc. Reports Material Event

[8-K] Quince Therapeutics, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K

Filing content is currently unavailable.

Source:

Stock QNCX logo
Quince

NASDAQ:QNCX

QNCX Rankings

#4804 Ranked by Market Cap
N/A Ranked by Dividends

QNCX Latest News

Aug 11, 2025
Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
Aug 7, 2025
Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP
Jul 16, 2025
Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
Jul 10, 2025
Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board
Jun 25, 2025
Quince Therapeutics to Participate at A-T Society’s 2025 A-T Clinical Research Conference

QNCX Latest SEC Filings

Aug 14, 2025
[SCHEDULE 13G] Quince Therapeutics, Inc. SEC Filing
Aug 11, 2025
[10-Q] Quince Therapeutics, Inc. Quarterly Earnings Report
Aug 11, 2025
[8-K] Quince Therapeutics, Inc. Reports Material Event
Aug 5, 2025
[424B5] Quince Therapeutics, Inc. Prospectus Supplement (Debt Securities)
Jul 25, 2025
[S-3] Quince Therapeutics, Inc. Shelf Registration Statement

QNCX Stock Data

89.70M
39.51M
11.12%
23.1%
1.65%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
SOUTH SAN FRANCISCO